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Background: The societal economic burden of herpes zoster in Sweden is not well described today. This study is a
top-down analysis of Swedish registers with the objective to describe the burden of herpes zoster and post-
herpetic neuralgia in Sweden during 2011.
Methods: Data for inpatient care; outpatient primary and specialized cares; the prescriptions of drugs, sick leave
and the number or diagnostic tests were collected from Swedish national databases. The incidence of the disease
was estimated based on the number of prescriptions of antiviral drugs.
Results: The incidence of herpes zoster was estimated to 315 and 577 cases per 100,000 people for patients at all
ages and > = 50 years, respectively. Almost 30,000 patients at all ages were diagnosed with herpes zoster and the
societal cost to treat these patients, including the cost to treat those patients who later developed post-herpetic
neuralgia, added up to nearly 227 MSEK (31.6 M€) which corresponds to 7,600 SEK (€870) per patient. The main
contributors to the total cost for the treatment of HZ patients were primary care (43 %); sick leave (28 %); hospitalization
(10 %) and specialist care (7 %). Medication was a relatively small contributor with 8.5 MSEK (4 %; 1.0 M€) to the overall
costs for patients at all ages. The corresponding total cost including only patients 50 years and older was 168 MSEK
(19.2 M€) or 8,200 SEK (€939) per patient.
Conclusions: The current study demonstrates that the burden of herpes zoster is significant in Sweden. The society,
the health care payers and the patients potentially have a lot to gain by introducing a vaccination program to patients
50 years and older and as a consequence reduce the economic and clinical burden of herpes zoster and post-herpetic
neuralgia.Background
Herpes zoster (HZ), also known as shingles, results from
reactivation of latent varicella-zoster virus (VZV) infec-
tion residing in the spinal and cranial sensory ganglia.
The initial infection of VZV usually occurs during child-
hood and manifests clinically as chickenpox. HZ as a
subsequent reactivation, more seldom as a result of re-
infection, of VZV presents as a clinical syndrome char-
acterized by a unilateral radicular pain and avesicular,
distributed cutaneous rash [1]. The annual HZ rate in
the general population has been estimated to be 3–6
cases per 1,000 person-years in the United States (US),
the United Kingdom (UK) and Europe [2–6], and the* Correspondence: Jonas.nilsson@optum.com
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unless otherwise stated.estimated average lifetime risk of HZ was approximately
30 % reported from UK and Canadian studies [7]. The
incidence and severity of HZ increase markedly with ad-
vancing age, about half of all cases occur amongst indi-
viduals 60 years old or older. In Sweden, a recent
burden of illness study on HZ conducted by Studahl
et al. [8] found similar results by analyzing data from
Swedish national registries during 2006–2010. It re-
ported that 2.7 per 1,000 persons were prescribed anti-
viral treatment for HZ every year and the prescription
rate increased with age [8]. The overall hospitalization
rate for HZ patients over 80 years was approximately
three-fold higher than for HZ patients aged 70–79 years
[8].
The most frequent complication of HZ is post-
herpetic neuralgia (PHN) usually defined as a neuro-
pathic pain syndrome that persists or develops more
than three months after the acute HZ infection and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Antiviral medications and specific packages§ used for
the treatment of HZ
Drugs ATC* DDD** Days Package
size
Aciclovir J05AB01 800mg × 5 7 35
Famciclovir J05AB09 500mg × 3 7 21
Valaciclovir J05AB11 500mg × 2 ×
3
7 42
*ATC = Anatomic Therapeutic Chemical; **DDD=Defined Daily Dose; §The same
package sizes were also used by Studahl et al. ([8] and personal communication)
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severity of PHN also increase with advancing age.
Among individuals who have had acute HZ, it is esti-
mated that about 20 % of those aged 60 years or older
and more than 30 % of those over 80 years develop PHN
[9]. Approximately 90 % of these complain that pain is a
predominant symptom, often refractory to treatment,
and about 2 % may suffer from pain for many years [9,
10]. The burden of HZ and PHN placed on health care
systems is therefore considerable.
The burden of HZ in Sweden from a clinical perspec-
tive has been discussed in a previous study by Studahl
et al. [8] for the years 2006–2010. The objective of the
current study is to assess the burden and societal costs
for HZ and PHN in Sweden during 2011.
Methods
Data that has been analyzed in the current study were
taken from Swedish national databases and were not
based on patient level data; hence, an ethical approval
was not needed and no additional permission was
needed. Costs were presented as 2013 Swedish kronor
(SEK), key costs ware also given in Euros within
brackets. Costs were inflated to 2013 using the Con-
sumer Price Index (CPI) taken from Statistics Sweden
where necessary; Conversion rate SEK to Euros average
during 2013: 8.6494], and the resource utilization was
summarized for the year 2011. All costs and values ob-
tained from the Swedish national databases were pro-
vided as unweighted means based on aggregated data
across 2011. Information regarding the dispersion
around the unweighted mean was not available and,
therefore, the uncertainty will be tested in sensitivity
analysis (see below).
Target population
The main analyses presented in the current study focus
on the costs for patients at all ages diagnosed with HZ
and PHN. The age dependent incidence of VZV infec-
tions manifested as chickenpox versus HZ has been de-
scribed by Yih et al. [11], Jumaan et al. [12] and Péréz-
Farinos et al. [13]. Based on these studies, and the fact
that only patients 50 years and older are eligible for vac-
cination in Sweden, it was also of interest to present the
cost and incidence specifically for these patients in
addition to the costs and incidence for all patients.
HZ and PHN Incidence
The incidence of HZ was estimated from the number of
prescriptions of antiviral drugs with specific package
sizes as described in Table 1. Prescriptions were obtained
from the Swedish National Pharmacy Register (SNPR)
covering close to 100 % of the prescribed medications.
However, the number of antiviral prescriptions wascorrected slightly since not only HZ patients are pre-
scribed antiviral medications (see section Drug treat-
ment below). The incidence reported by Studahl et al.
[8] was from 2006–2010 but was updated with data from
2011 in this study. The share of HZ patients who devel-
oped PHN was taken from Gauthier et al. [14]. Here the
share of patients, who were diagnosed with HZ and de-
veloped PHN within three months in the UK, was used
as the incidence of PHN also in Sweden. The incidence
was reported as the number of patients who were diag-
nosed with HZ or PHN per 100,000 Swedish people dur-
ing 2011.
Mortality
Deaths related to HZ (ICD-10: B02) were collected from
the Swedish Causes of Death Register covering all the
people who died and were registered as living in Sweden
until 2011.
Inpatient care
The Swedish Association of Local Authorities and Re-
gions [15] are conducting a country-wide project to sup-
port the calculation of patient-related costs of care. As a
result, the cost per patient for the treatment of various
diagnoses is publically available via the KPP (KPP stands
for cost per patient) database [15]. Although the KPP
database does not cover the entire country yet, the costs
for the treatment of HZ (DRG= 421) and PHN (DRG=
020) were taken from this database.
The number of inpatient treatments of HZ as primary
cause (ICD-10: B02) and PHN as primary cause
(ICD-10: G53.0), as well as the average duration of
hospitalization, were taken from the Swedish National
Patient Registry (held by the Swedish Board of Health
and Welfare).
Outpatient specialist care
Statistics covering specialist care performed by physi-
cians who are not general practitioners (GPs), are avail-
able from the Swedish National Patient Registry. The
number of outpatient visits to specialist care with HZ or
PHN as a primary or secondary diagnosis during 2011
was included in the analyses. A visit to a specialist was
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age of the cost from visiting an ophthalmologist, neur-
ologist, dermatologist, pain specialist or an infection
specialist). Unit costs for the visits to the different types
of care were derived as the average cost from the differ-
ent regions and county councils in Sweden [16–20] as
presented in Table 2.
Outpatient primary care
Primary care data for HZ and PHN patients during 2011
were extracted from Västra Götaland county council
(VGR) and scaled to the entire Swedish population
based on the share of the population the VGR county
council is covering, which currently is 16.8 % (1.59 M
people) of the Swedish population. The VGR register all
care (primary and specialist) consumed by its population
in a local database. Primary care predominantly involved
visits to general practitioners, doctors on call or home
care visits. All the unit costs are listed in Table 2. The
cost for a physician on call was estimated to be 50 %
higher than a regular visit to a GP as suggested in the
pricelist from South-East Sweden [16].
Diagnostic tests
Herpes Zoster is predominately diagnosed based on the
clinical situation; however, a couple of diagnostic tests
are being used for patients with HZ or suspected HZ.
The number of diagnostic tests performed with HZ pa-
tients was available in the Stockholm county council
(Faktureringsunderlag Medicinsk Service (FUMS)). The
tests used for HZ patients included IgG, a serologic la-
boratory test used to identify previous exposure to VZV
and immunity, and second, measuring the presence of
DNA in blisters or used as a laboratory diagnostic test of
VZV-infected patients. The total number of tests per-
formed in Sweden during 2011 was derived based on the
share of the total population covered by the Stockholm
county council, which corresponds to 22.1 % (2.09 M
people). The cost per diagnostic test (940 SEK (€109))Table 2 Cost per outpatient visit to primary and specialist cares
Care Average cost per
visit (SEK) (SD)
HZ:Number o
all ages (> =
Outpatient care (primary)
General practitioner (GP) 1 544 (214) 47 047 (35 4
Physician on call 2 316 (321) 10 534 (6 90
Home care* 422 (NA) 1 848 (1 765
Outpatient care (specialist)
Specialist visit** 2 399 (732) 6 517 (5 292
*Primary care organized home care; **Average costs (ophthalmologist, neurologist,
Norrland county council, Västra Sjukvårdsregionen, Sahlgrenska hospital, Stockholm
Södra Sjukvårdsregionenincluding IgG and DNA was taken from the list price at
a commercial vendor [21].
Drug treatments
Prescriptions of drugs to patients at all ages and > =50
years, during 2011 were extracted from the SNPR. In
general, HZ patients are prescribed antiviral drugs only
in the package sizes listed in Table 1, with enough pills
to cover seven days of treatment. Therefore, the corre-
sponding number of patients was used as a measure of
the incidence of HZ during 2011 [8]. Antiviral drugs can
also be prescribed to patients with other infections than
VZV, e.g., primary infections with VZV, as outlined by
Studahl et al. [8]. To correct for this, prescriptions with
the words: simplex, genital, mouth, labial, varicella,
prophylaxis or chickenpox in the patient information
field were excluded, amounting to 12 % of the antiviral
prescriptions [8].
Among those patients who were prescribed antiviral
drugs, other drugs related to the treatment of HZ and PHN
were also collected, including non-selective monoamine
re-uptake inhibitors (e.g., amitryptiline), antileptics (e.g.,
gabapentin and pregabalin), opiods (e.g., tramadol) and
anti-depressants (e.g., venlafaxine). As the number of pre-
scriptions of other drugs than antiviral drugs was based on
the same patients who were prescribed antiviral drugs, the
number of prescriptions of other drugs was adjusted down-
wards by 12 % to correct for the patients with other infec-
tions than VZV (see above).
The cost per package was assumed to be equal to the
cheapest competitor in case no price was available in
Farmaceutiska Specialiteter i Sverige (FASS) [22].
Sick leave
Data regarding sick leave for patients who were off sick
more than 14 days due to HZ/PHN during 2011 were
obtained from the Swedish Social Insurance Agency
(SSIA). Sick leaves shorter than or equal to 14 days
are not registered by the SSIA since employers aref visits;
50 years)
PHN: Number of visits;
all ages (> = 50 years)
Source
79) 882 (799) [17, 18, 20]
4) 12 (0) 50 % higher than
GP visit [16]
) 30 (30) [19]
) 617 (570) Average of cost to
specialists**
dermatologist, pain specialist, infectious specialist) calculated from pricelist in
and Gotland county council, Linköping county council and
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the first two weeks of sick leave. Therefore, the number
of days of sick leave below this threshold was estimated
based on data in a previous study. Drolet et al. [23]
found that the majority of employed HZ patients (64 %)
reported an average absence from work of 27 h during
the first 30 days of sickness. White et al. [24] found that
HZ patients (18–65 years) in the US were on sick leave
on average 26.5 h the first year after diagnosis; no speci-
fication on how these hours were distributed during the
index year was provided in the study. In a telephone sur-
vey performed in the US by Singhal et al. [25] it was
found that patients between 50–64 years were on aver-
age away from work 31.6 h per HZ episode. In those
cases where the duration of the HZ episode was less
than a month, patients lost on average 12.1 h of work. In
addition to the absenteeism (time away from work),
presenteeism-related work loss (for those who go to
work despite their illness) could not be estimated but
could add to the sick-leave related work loss as shown
by Drolet et al. [23] and Singhal et al. [25].
In the current study, the work loss reported by Drolet
et al. [23] (27 h the first 30 days from index date) was
used as an estimation of the work loss for Swedish HZ
patients during the first 13 days of illness. Thus, patients
were off sick on the average 3.38 days (assume eight
hours of work per day; 27/8 = 3.38) if the sickness period
was less than 14 days.
The number of employed HZ patients was calculated
based on the employment rate (per 10-year age groups
from 15 to 74 years old) , including both males and fe-
males, in Sweden during 2011 obtained from Statistics
Sweden [26].
To calculate the cost for lost production for patients
on sick leave the average monthly salary was obtained
from Statistics Sweden [26]. The daily wage was derived
assuming 40 h of work per week and an employer’sFig. 1 The incidence of herpes zoster (HZ) and post-herpetic neuralgia (PHcontribution of 31.42 % [27] yielding 1,742 SEK (€201)
per day.
Sensitivity analysis
Parameters that were estimated rather than obtained from
any registers, i.e., the number of sick leave days shorter than
14 days, the GP consultation cost, daily hospitalization cost
and the cost of drugs, were included in one-way sensitivity
analyses experiments. The base case values were increased
with 25 % for all parameters except for the number of short
term sick leave days that was increased with 50 %. The im-
pact on the total cost of HZ, including patients at all ages,
was estimated for each experiment.
Results
Incidence
The incidence of HZ during 2011 is presented per age
group in Fig. 1. In total, 29,900 (all ages) and 2,860
patients (> = 50 years) were diagnosed with HZ and
PHN in Sweden during 2011, respectively. The corre-
sponding number for patients 50 years and older with
a diagnosis of HZ was 20,446. The incidence of HZ is
clearly higher for the group of patients older than 50
years compared to the whole population with 577 and
315 cases per 100,000 persons, respectively (Fig. 1).
The incidence of PHN was only estimated for patients
older than 50 years to 81 cases per 100,000 persons.
Mortality
Only eleven people died from HZ in Sweden during
2011 (0.12 per 100,000 people) and it was assumed that
death did not contribute with any significant cost to the
overall burden of HZ.
Health care utilization
In Table 3, the number of visits to the different types of
care utilized for the treatment of HZ and PHN areN) during 2011 (incidence per 100,000 persons)
Table 3 Number of health care visits for HZ and PHN patients during 2011 including: inpatient care (hospitalization), outpatient care
(primary) and outpatient care (specialist)
Type of care Diagnosis Number of visits; all ages (> = 50 years) Total cost; all ages (> = 50 years) (SEK)
Inpatient care (hospitalization)* HZ 725 (640) 23 342 200 (21 784 000)
PHN 222 (217) 11 107 400 (11 014 000)
Outpatient care (primary) ** HZ 59 457 (44 147) 97 876 300 (71 524 300)
PHN 924 (829) 1 402 800 (1 246 300)
Outpatient care (specialist)* HZ 6 517 (5292) 15 634 300 (12 695 500)
PHN 617 (570) 1 480 200 (1 367 400)
Total: 150 843 200 (119 631 400)
*Swedish National Patient Registry; **Numbers from Västra Götaland County Council scaled to Sweden based on share of the population
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and specialist) care. Clearly, the dominating medical re-
source use for HZ was outpatient visits to a physician with
almost 60,000 visits followed by outpatient visits to a spe-
cialist with 6,500 visits in 2011. The number of visits is real
world data and, therefore, each visit will incur a cost regard-
less if a patient contributed with more than one visit.
From the KPP database the costs per HZ and PHN hospi-
talizations were taken and equaled 41,000 SEK (€4,800) and
32,000 SEK (€3,700), corresponding to 7.87 and 5.44 days of
hospitalization, respectively. The daily hospitalization costs
were calculated for HZ and PHN to 5,261 SEK (€608) and
5,840 SEK (€675), respectively. The average hospitalization
time for patients older than 50 years was calculated to 6.47
days and 8.69 days for HZ and PHN, respectively, based on
data from the Swedish National Patient Registry. Note, that
the number of hospitalization days, used to estimate the
total hospitalization costs, were taken from the Swedish
National Patient Registry, rather than the KPP-database, as
the former was based on all registered hospitalisations. Only
a small part 2.7 % and 5.5 % of the HZ and PHN patients
50 years and older, respectively, were hospitalized while
incurred 13 % of the total costs.
The treatment of HZ patients incurs clearly more resource
use than the treatment of PHN patients with estimated costs
for hospitalization of 23 and 11 MSEK (2.7 and 1.3 M€), pri-
mary care of 98 and 1 MSEK (11 and 0.1 M€) and specialist
care of 16 and 1 MSEK (1.8 and 0.1 M€), respectively (Fig. 2).
The share of hospitalization costs for PHN patients was
higher relative to the cost for HZ patients as compared to
the corresponding costs for the outpatient cares.
The overall health care costs for HZ and PHN patients
add up to over 151 MSEK (17.6 M€) where the cost for
primary care is dominating. For patients 50 years and
older the corresponding cost is 120 MSEK (14 M€)
which is 79 % of all the health care costs.Diagnostic tests
In Sweden, the total cost for diagnostic tests performed
to establish the HZ diagnosis was estimated to around 4MSEK (0.5 M€; IgG and DNA with 3 MSEK and 1
MSEK, respectively) during 2011 based on 3,686 and
812 numbers of tests for IgG and DNA, respectively. In-
cluding only patients > = 50 years the total cost was al-
most 3 MSEK (0.3 M€).
Drug treatments
The total costs of drug treatment were derived from the
number of prescriptions of antiviral drugs and non-viral
drugs to HZ/PHN patients and the cost per prescription
[22] (Table 4). In total, the antiviral drugs and non-viral
drugs contributed with around 8.5 MSEK (0.99 M€) to
the overall burden of HZ in 2011 in all ages. Out of the
6 MSEK (0.7 M€) that was spent on anti-viral drugs, 72 %,
24 % and 5 % were spent on valaciclovir, aciclovir and
famciclovir, respectively. Non-viral drugs included ami-
tryptiline (mono-amine reuptake inhibitors), gabapentin
and pregabalin, tramadol (opioids) and venlafaxine
(antidepressant). Patients 50 years and older accounted
for 69 % (5.9 MSEK; 0.7 M€) of the total drug cost.
Sick leave
During 2011, 370 patients with the diagnosis HZ were
on sick leave for an average length of 51 days, based on
information from the SSIA. In addition, approximately
8,500 patients were on sick leave less than 14 days with
an average length of 3.4 days. The major societal eco-
nomic consequence of sick leave is cost for lost product-
ivity as presented in Table 5. Out of the 22,800 HZ
patients in working age with reported sick leave (20–74
years) 13,800 were employed during 2011.
The total sick leave cost for all patients during 2011
was estimated to 63.2 MSEK (7.3 M€) (40.0 MSEK (4.6
M€) for patients > =50 years).
Total costs
In Sweden, during 2011, the overall societal cost of HZ
and PHN was estimated to 227 MSEK (26.2 M€) includ-
ing patients at all ages which corresponds to on average
7,600 SEK (€880) per HZ patient. If only patients 50
years and older were included the overall cost was
Fig. 2 Break down of costs for the burden of HZ and PHN in Sweden 2011 for all ages (grey bars) and > =50 years (black bars)
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The main contributors to the total cost for the treatment
of HZ patients were primary care (43 %); sick leave (28
%); hospitalization (10 %) and specialist care (7 %).
Medication was a relatively small contributor with 4 %
(8.5 MSEK; 0.99 M€) to the overall costs for patients at
all ages.
Sensitivity analysis
To test how sensitive the overall cost was to changes in
the estimated number of short term sick leave days these
were increased with 50 % from 3.4 days to 5.1 days per
employed HZ patient and year. The total cost increased
from 227 MSEK (26.2 M€) in the base case to 242
MSEK (6 % increase; 28.3 M€). Sensitivity analyses were
also conducted for a few other estimated parameters: in-
creasing the GP consultation cost with 25 % increased
the total cost with 8 % to 245 MSEK (28.6 M€); increas-
ing the daily hospitalization cost with 25 % increased the
total cost with 4 % to 235 MSEK (27.2 M€) and similar
for the drug cost increased the total cost slightly to 229
MSEK (26.5 M€).
Discussion
During 2011, almost 30,000 patients were diagnosed
with HZ/PHN and the societal costs to treat these pa-
tients, including the costs to treat patients who later de-
veloped PHN, added up to nearly 227 MSEK (26.2 M€).Table 4 Costs for drugs prescribed to HZ patients at all ages
during 2011. In parenthesis prescriptions for patients > =50 years
Drug Number of prescriptions,
all ages (> = 50 years)*
Total cost all ages
(> = 50 years) (SEK)
Antiviral 32 640 (22 195) 5 980 800 (3 925 200)
Non-viral 22 734 (18 022) 2 577 500 (1 962 600)
Total: 8 558 300 (5 887 800)
*The number of prescriptions was adjusted downwards with 12 % to correct
for prescriptions to other diagnosis than HZThe corresponding cost when only patients 50 years and
older were considered adds to 168 MSEK (19.5 M€). In
the study by Studahl et al. [8] it was estimated that just
above 28,000 patients received antiviral drugs during
2010. They also demonstrated evidence of an increasing
number of prescriptions of antiviral drugs (and diagno-
ses of HZ) from 2006 to 2010 in Sweden.
A number of studies have studied the cost of HZ and
PHN covering different components and populations
with a cost per patient range from 1,000 SEK (€116) to
over 20,000 SEK (€2,300). In Spain, during 2006–2007 a
study published by Cebrían-Cuenca et al. [28] estimated
the cost per HZ patient from a societal perspective to
€378 (around 3,300 SEK). In this study, the most import-
ant contributing cost factors were medications, followed
by primary care physician visits, accounting for 37 %
and 23 % of the societal costs, respectively. No hospitali-
zations were considered in this study. Gauthier et al.
[14] estimated the combined mean total cost of out-
patient and inpatient health care to £103 (1,042 SEK or
€122) per HZ case. In addition, the cost per PHN epi-
sode was estimated to £397 (3,997 SEK or €466). Most
of the costs were attributed to primary care (74 %). In
an Italian retrospective, population-based study [29] the
costs per HZ and PHN episodes were estimated. The
costs associated with inpatient and outpatient care per
HZ case were €2,592 per patient (22,419 SEK) compared
to €123 per patient (1,064 SEK), respectively. The corre-
sponding figures per PHN case were €2,806 (24,270 SEK)
and €446 (3,858 SEK), respectively. Scott et al. [30] showed
that the medical cost were highest in those aged over 65
years and societal costs highest in those aged under 65
years. However, the overall cost of HZ during the first six
months was estimated at £524 per patient (in 2003 UK£;
4,489 SEK or €524). In that study, it was also suggested
from a regression analysis that increasing age, the pres-
ence of immune compromising conditions and the use
of antivirals were associated with increased costs to
Table 5 Number of sick leave days (<14 days and > =14 days) and productivity losses during 2011 for HZ
Age groups (years) Number of employed HZ
patients* (> = 50 years)
Number of HZ patients
on sick leave**
Lost production cost (SEK)***
(> = 50 years)
Sick leave > =14 days 13 822 (6 689) 370 32 876 300 (15 909 500)
Sick leave <14 days 13 822 (6 689) 8 476 30 321 300 (24 119 200)
Total: 63 197 600 (40 028 700)
*Statistics Sweden; **Swedish Social Insurance Agency; ***Patients were off sick on average 51 days if sick leave > =14 days and 3.38 days if <14 days
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ated with decreased medical costs. Finally, in a French
study by Mick et al. [31] the cost per patient for the treat-
ment of patients, older than 50 years, with HZ and PHN
was estimated to €932 (8,061 SEK) which corresponds to
what was found in our study (8,240 SEK per patient).
As different approaches to estimate the cost of HZ
and PHN have been used in all of the above studies, dir-
ect comparisons with our results are not straightforward.
A couple of the studies (Gauthier et al. [14] and Gialloreti
et al. [29]) indicated that primary care was the main cost
contributor which we also found in our study. Cebrían-
Cuenca et al. [28] estimated the cost per patient to 3,200
SEK (€370) per year (without hospitalizations) while Scott
et al. [30] reported 4,489 SEK (€519) per six months. Both
studies are in line with the 7,600 SEK (€879) per patient
per year in our study.
The current study includes both direct and indirect
cost which was not the case in all of the studies above. It
is also a strength of the current study that register data,
covering most of Sweden, were possible to collect for in-
patient care, outpatient specialist care, prescribed medi-
cations and long term sick leave for HZ and PHN
patients. A limitation of the current study, is the number
of patient in inpatient care that has been estimated from
ICD-10 code for HZ as the primary cause. When includ-
ing patients also with HZ as the secondary cause, the
number of hospitalizations increase by approximately 90 %
[8]. Another limitation is that regional data (i.e., the number
of diagnostic tests from Stockholm county council and out-
patient primary care from Västra Götaland county council)
has been extrapolated to the whole of Sweden. However,
there is no data indicating large regional differences in
HZ. Therefore, it is likely that the primary care cost esti-
mated for Sweden is reliable.
In line with the findings by Jumaan et al. [12] and
Pérez-Farinós et al. [13] our study showed that both the
incidence and burden of HZ was larger for patients
above 50 years old.
There is a risk that the incidence has been over-
estimated since it was derived from the prescriptions of
antiviral drugs in specified package sizes, which also can
be prescribed to patients with other diagnoses than HZ.
However, as postulated by Studahl et al. [8] it is likely
that the number of diagnosed HZ patients exceeds the
number prescriptions.A very low mortality was identified due to HZ with
only 11 fatalities identified. Considering the minimum
yearly incidence of VZV central nervous system (CNS)
disease of 1.8 per 100,000 with a significant mortality in
encephalitic cases and reports of cerebral vasculitis com-
plications due to VZV in the mistaken for common
stroke, this might be an underestimate of the true VZV
associated both morbidity and mortality [32, 33].
To the best of our knowledge no registry in Sweden
contains data for short term sick leave i.e., shorter than
14 days. The assumption made here was 3.4 days per
worker patient based on Drolet et al. [23]. Sensitivity
analysis showed that the total cost increased with 6 %
when the number of short term sick leave days was in-
creased with 50 %. As the actual number of short term
sick-leave days is not available in Sweden, future studies
could benefit from acquiring more precise data for this
variable. Moreover, in the current study it was decided
not to include the cost for patients to travel to the phys-
ician or the hospital in our analysis. This would have in-
cluded the cost for public transportation or the cost for
travel by car to the nearest hospital or primary care cen-
ter. Since the incidence of HZ/PHN increases with age
many patients are old and may need help by an accom-
panying person when they visit the physician. This per-
son is often a relative who needs to take time off from
work to accompany the patient. The societal cost for
productivity losses for the carer has not been taken into
account in this study. Although the travel and carer cost
most likely would not be insignificant, the estimations
would have been based on crude assumptions, e.g., dis-
tance to hospital, type of transportation and who the
average carer is. Since no real data was available to sup-
port any assumptions it was decided to exclude the
transportation costs and the productivity loss of the
carer in this study.
It was found that a considerable part of the societal cost
for the treatment of HZ and PHN (168 MSEK (19.2 M€)
corresponds to 74 %) are incurred by patients 50 years
and older (corresponding to 78 % of the cases of HZ and
PHN). Zostavax, a high-titer lived attenuated virus vac-
cine, is indicated for the prevention of HZ and PHN in
adults 50 years of age and older in the EU. Its efficacy has
been tested in a large randomized, double-blind, placebo-
controlled trials (Shingles Prevention Study, SPS) [34].
This study reported that the vaccination reduced the
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38,546 immune competent adults aged 60 and older
over a mean surveillance period of 3.1 years. It reduced
the burden of illness due to HZ by 61.1 %, in that vac-
cinated individuals who developed HZ had a shorter
duration, reduced disease severity and discomfort from
pain compared to individuals from the placebo group
who developed HZ [34]. The effect of the vaccine was
confirmed by Schmader et al. [35] in the Zostavax Effi-
cacy and Safety Trial (ZEST), where the incidence of
HZ was reduced significantly (vaccine efficacy of 69.8
%) in patients between 50–59 years old and was well
tolerated.
Conclusions
The clinical and economic burden of HZ and PHN is
significant in Sweden and the current study estimates
that 74 % of the total costs are incurred by patients 50
years and older. Therefore, there is a potential for redu-
cing the societal burden of these diseases through vac-
cination programs targeted at this group of patients that
is likely to increase in the future. Although there are
costs associated with a vaccination program, these need
to be balanced against the likely reduction in disease
burden and potential improvement of quality-of-life for
many patients.
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